Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Andecaliximab in Healthy Subjects
NCT02209987Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of andecaliximab in ulcerative colitis (UC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Pharmacokinetic profile of GS-5745 at Week 8. Started Aug 2014; status: completed.
02
Drugs
andecaliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02209987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209987.